|Bid||0.00 x 800|
|Ask||162.00 x 1000|
|Day's range||158.52 - 161.66|
|52-week range||114.04 - 187.72|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||18.91|
|Earnings date||28 Jul 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||153.73|
3M (MMM) faces risks from the pandemic-related uncertainties, evident from a sales decline in April. However, cost-reduction measures and huge demand for respirators will likely support results in the second quarter.
3M (NYSE:MMM) announced today that Monish Patolawala is appointed senior vice president and chief financial officer, effective July 1, 2020. Patolawala will succeed Nick Gangestad, who has announced his intention to retire. Gangestad will stay on through July 31, 2020, to ensure an orderly transition.
These dividend stocks can produce significant income without putting your portfolio in harm's way.
3M's (NYSE: MMM) chief executive officer Mike Roman gave a presentation at a Bernstein investment conference at the end of May and what he had to say helped confirm 3M's status as one of the most interesting investment opportunities in the industrial sector. It's not that the company's operational performance has been great over the last few years, or that its end markets overall aren't being hit by the COVID-19 pandemic. Instead, the case for buying 3M stock is based on the idea that Roman can significantly improve performance in a company that is now valued lower than its peers.
3M (MMM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Rising revenues from its healthcare segment weren't enough to make up for the pandemic-related sales declines elsewhere in the industrial conglomerate
3M (NYSE: MMM) today reported sales information for the month of April 2020. The company withdrew its full-year 2020 outlook on April 28, 2020, due to the uncertain impact of the COVID-19 pandemic, and committed to provide monthly updates until it is better able to forecast future performance.
The 3M Board of Directors (NYSE:MMM) today declared a dividend on the company’s common stock of $1.47 per share for the second quarter of 2020. The dividend is payable June 12, 2020, to shareholders of record at the close of business on May 22, 2020.
3M has been awarded two contracts through the U.S. Department of Defense to further expand American production of N95 respirators.
Newly designed powered air-purifying respirators (PAPRs), developed by Ford in close collaboration with 3M, are on the way to health care workers fighting COVID-19.
With the U.S. importing mass quantities of personal protective equipment, medical gear, COVID-19 tests, and more, a lot of substandard and outright counterfeit gear is landing on our shores.
NEW YORK (Reuters) - 3M Co won an injunction from a federal judge against a New Jersey company it accused of illegally using its trademarks to sell 3M-branded N95 respirator masks at inflated prices to exploit the coronavirus pandemic. U.S. District Judge Loretta Preska in Manhattan on Monday blocked Performance Supply LLC of Englishtown, New Jersey from using 3M's name and logo, or posing as an authorized 3M distributor, to help sell masks. 3M, based in St. Paul, Minnesota, is the world's largest maker of N95 masks, which are designed to filter 95% of airborne particles.
Multi-industry industrial 3M Company (NYSE: MMM) represents one of the most interesting investment options in its sector. Earlier in the year, the market wasn't too impressed with 3M's fourth-quarter 2019 results. First, if you exclude the restructuring charges 3M would have hit the high point of its first-quarter guidance range.
3M today announced that it has completed the sale of substantially all of its drug delivery business to an affiliate of Altaris Capital Partners, LLC., for approximately $650 million in total consideration, including cash, an interest-bearing security, and a 17 percent noncontrolling interest in the new company, Kindeva Drug Delivery, that will operate the business.
The vendors tried to sell respirators to officials in Florida, Wisconsin and Indiana at highly inflated prices, 3M said, adding that they were not connected with the company. N95 respirators, which are designed to filter 95% of airborne particles, are among personal protective gears most needed by medical professionals battling the coronavirus outbreak. The company said one case claimed to have up to five billion respirators at inflated prices, falsely affiliating themselves with 3M.
3M has filed five legal actions in federal courts in Florida, Wisconsin and Indiana as part of its global effort to protect the public and combat fraud and counterfeiting. The lawsuits involve separate defendants who attempted to target government officials with fraudulent offers to sell N95 respirators—in one case claiming to have up to five billion respirators—at inflated prices, all while falsely affiliating themselves with 3M.
Industrial giant 3M reported rising quarterly profits Tuesday as it ramps up production of N95 masks while combatting price-gouging and fraud during the coronavirus outbreak. The company manufactures a wide range of products used in myriad industries, but has become prominent during the COVID-19 outbreak as one of the only producers of N95 "respirator" masks which can protect against the virus. 3M experienced a 21 percent surge in sales in its health care business during the first quarter, a key driver of a 45 percent jump in first-quarter profits to $1.3 billion.